Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy

✍ Scribed by Michael Lübbert; Carsten Müller-Tidow; Wolf-Karsten Hofmann; H. Phillip Koeffler

• Publisher: John Wiley and Sons
• Year: 2008
• Tongue: English
• Weight: 213 KB
• Volume: 104
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.21770

✦ Synopsis

Abstract

We describe several recent advances in our understanding and treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) including the use of cytogenetics to classify these diseases and to identify therapies that are specific for the abnormalities. Cell lines have provided readily available and very relevant models to understand these diseases. The two clear successes include the use of retinoic acid for acute promyelocytic leukemia and tyrosine kinase inhibitors (e.g., imatinib) for chronic myelogenous leukemia. Very recent results suggest a particular activity of lenalidomide, an analogue of thalidomide, in MDS patients with deletions of the long arm of chromosome 5 (so‐called 5q minus syndrome), and notable activity of azanucleoside DNA demethylating agents in MDS with loss of chromosome 7. However, for the vast majority of cytogenetic abnormalities found in AML/MDS, no specific therapies have been identified. The use of a variety of molecular biology techniques have identified a large number of genomic abnormalities; the challenge of the next several decades is to identify specific therapies for these molecular defects. J. Cell. Biochem. 104: 2059–2070, 2008. © 2008 Wiley‐Liss, Inc.